Molecular profile
- Sequence
- VIKLSGRELVRAQIAISGMSTWSKRSL
- Molecular Formula
- C318H164N84O40
- Molecular Weight
- (B7-33)H2, GTPL9321
Peptide research profile
B7-33
B7-33 is a peptide currently undergoing active research, primarily due to its potent anti-fibrotic properties. Researchers are investigating its potential to reduce fibrosis in conditions ranging from heart failure and lung inflammation to kidney disorders and more. Animal studies have shown that B7-33 can significantly diminish fibrosis by approximately 50%, leading to improved survival rates following injuries.…
Dosing literacy
Dosing & scaling, explained
The moderated mass amounts below are retained for comparison. Near-duplicates, mix-dependent volumes and device markings are excluded. This is educational source context—not a protocol or recommendation.
Recorded amount context
Mass amounts available for comparison
- Lower range200 mcgDose
Recorded example with no verified study backing; shown for amount literacy only.
- Mid range800 mcgDose
Recorded example with no verified study backing; shown for amount literacy only.
Only mcg or mg amounts are retained. The calculator derives mL, syringe units or pen clicks from the current vial strength, water volume and device.
Schedule literacy
No independently verified schedule
Evidence context
No clinical amount or schedule is inferred from this material. Source verification is pending, and every displayed amount remains educational context rather than guidance.
Research best practices
Storage, handling and interpretation
Product identity
Verify the exact compound, formulation and amount against the product label or certificate before calculation.
Storage & handling
Follow the product label, certificate and validated laboratory SOP; no universal storage assumption is applied here.
Prepared solutions
Label concentration and preparation date, use sterile technique where applicable, and follow a validated stability protocol.
Research orientation
What researchers are exploring
These themes organize the educational information currently available. Individual claims remain under source review and are not treatment claims.
- 01
Ease of Production
Advantages of B7-33 production compared to native H2-relaxin
- 02
Research and the Heart
B7-33's effects on cardiovascular health and anti-fibrotic properties
- 03
Summary
Comprehensive overview of B7-33's therapeutic potential and applications
Evidence map
What is known—and what still needs verification
Available context is organized without assigning unsupported study models or evidence grades.
- Source review pending
Ease of Production
Advantages of B7-33 production compared to native H2-relaxin
- Source review pending
Research and the Heart
B7-33's effects on cardiovascular health and anti-fibrotic properties
Recorded protocol library
Amounts recorded for B7-33
These amount records are independent from vial strength, reconstitution volume and measuring device. A recorded source is not the same as study backing, and these values are not recommendations.
- 01
Dose · lower endpoint
200 mcg
Sign in for schedule, duration and source context.
- 02
Dose · upper endpoint
800 mcg
Sign in for schedule, duration and source context.
Technical reference
Identity, limitations and unknowns
Important limitations
- Individual claims and source links have not yet completed editorial verification.
- Evidence level, applicable study model, formulation, route and population remain unassigned.
Source review
1 links awaiting verification
- Source link · pubs.rsc.orgVerification pending · Source review pending